Manuel Ong, MD
Emergency Medicine · Carthage, MSNPI 1932158664
Payments from drug & device makers
Across 254 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$739
- AbbVie$730
- Novartis$499
- Otsuka America Pharmaceutical, Inc.$360
- Bard Peripheral Vascular, Inc.$284
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,019100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $739 |
| AbbVie(2 entities) | 60 | $730 |
| Novartis | 30 | $499 |
| Otsuka America Pharmaceutical, Inc. | 8 | $360 |
| Bard Peripheral Vascular, Inc. | 1 | $284 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $267 |
| Smith+Nephew | 5 | $252 |
| GSK | 18 | $244 |
| Amgen | 6 | $200 |
| Novo Nordisk | 11 | $183 |
| Abbott | 12 | $178 |
| Teva Pharmaceuticals USA, Inc. | 3 | $150 |
| Astellas Pharma US Inc | 8 | $112 |
| Organogenesis Inc. | 2 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Pfizer | 4 | $70 |
| Lundbeck LLC | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $64 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Bayer | 3 | $47 |
| Eisai Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Grifols USA, LLC | 3 | $36 |
| SK Life Science, Inc. | 2 | $35 |
| Merck | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Edwards Lifesciences | 1 | $26 |
| Harmony Biosciences LLC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Medtronic | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RotarexS 6 F x 135 cm$284
- REXULTI$231
- EVENITY$125
- BREZTRI AEROSPHERE$124
- AJOVY$124
- FARXIGA$115
- Santyl$115
- REGRANEX$115
- Oasis$115
How this compares
$5,019 in reported general payments places this provider in the 95th percentile of 443 emergency medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $123,284 |
| OzempicSemaglutide | 83 | $91,100 |
| JanuviaSitagliptin Phosphate | 101 | $81,358 |
| LinzessLinaclotide | 97 | $65,123 |
| MounjaroTirzepatide | 29 | $49,809 |
| Tresiba Flextouch U-200Insulin Degludec | 75 | $47,807 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $42,551 |
| JardianceEmpagliflozin | 88 | $39,192 |
| EntrestoSacubitril/Valsartan | 34 | $25,972 |
| FarxigaDapagliflozin Propanediol | 34 | $24,805 |
| Xtampza ErOxycodone Myristate | 20 | $23,203 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $22,899 |
| RybelsusSemaglutide | 12 | $20,288 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,676 |
| OxycontinOxycodone Hcl | 21 | $16,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $70 | $136,026344 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $183 | $127,578185 claims |
| MerckJanuvia | $30 | $81,358101 claims |
| AbbVieLinzess, Restasis | $730 | $73,257111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta, Lokelma | $739 | $59,536123 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $244 | $50,97986 claims |
| Lilly USA, LLCMounjaro | $15 | $49,80929 claims |
| Boehringer IngelheimJardiance | $28 | $39,19288 claims |
| NovartisEntresto | $499 | $25,97234 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $15,58750 claims |
| Johnson & JohnsonXarelto | $12 | $15,20545 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $4,98864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 emergency medicine providers in Mississippi.
Other emergency medicine in Carthage
- Stanley ThompsonSouthaven$466K
- Utsav NandiJackson$329K
- Richard SummersJackson$20K
- Stephen BoskovichPascagoula$13K
- Damon DarseyJackson$11K
- Kenneth WhittingtonHazlehurst$8K
- Samuel Richardson IiiJackson$8K
- Joseph PongettiJackson$5K
- Robert WalkerHazlehurst$5K
- Salvador ArceoBrandon$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.